Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK).
<h4>Background</h4>Sodium-glucose cotransporter 2 (SGLT2) inhibitors are widely used to reduce hyperglycemia. The present study investigated the effects of a SGLT2 inhibitor, empagliflozin, on hyperglycemia in a novel rat model of non-obesity type 2 diabetes with enlarged kidney (DEK).&l...
Guardado en:
Autores principales: | Ayaka Domon, Kentaro Katayama, Touko Sato, Yuki Tochigi, Hiroyuki Tazaki, Hiroetsu Suzuki |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7a40a4948b73485584bbc6c3ec61bdd7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Empagliflozin in type 1 diabetes
por: Mathieu C, et al.
Publicado: (2019) -
Empagliflozin: a new strategy for nephroprotection in diabetes
por: Anton Ivanovich Korbut, et al.
Publicado: (2017) -
Empagliflozin Ameliorates Free Fatty Acid Induced-Lipotoxicity in Renal Proximal Tubular Cells via the PPARγ/CD36 Pathway in Obese Mice
por: Chiang-Chi Huang, et al.
Publicado: (2021) -
Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes
por: Munir KM, et al.
Publicado: (2016) -
DEK-targeting DNA aptamers as therapeutics for inflammatory arthritis
por: Nirit Mor-Vaknin, et al.
Publicado: (2017)